Experience in reverse sequence procedures for esophageal cancer surgery
© Chung-Ping et al. 2015
Published: 16 December 2015
Despite different surgical techniques, conventional approaches for esophageal cancer surgery comprise of tumor resection followed by esophageal reconstruction.
Been a high volume cancer center, we aim to investigate the efficacy and safety of reverse sequence procedures (reconstruction first followed by resection) in treating esophageal cancer patients.
Being a high volume cancer center, we aim to investigate the efficacy and safety of reverse sequence procedures (reconstruction first followed by resection) in treating esophageal cancer patients.
After excluding 13 conversions (5 in reverse group, 8 in non-reverse group), the operation time, blood loss, and retrieved lymph nodes number, cervical anastomotic leak, and hospital stay were 468.6 vs. 506.3 min (p = 0.004), 420.1 vs. 286.7 cc. (p = 0.012), 37.4 vs. 29.6 (p = 0.002), 20 vs. 15 cases (p = 0.008), and 14.4 vs. 17.0 days (p = 0.034), in reverse group and non-reverse group, respectively. There were 2 hospital mortalities, complete pathologic response was obtained in 44 of the 119 neoadjuvant patients (37.0%), and the cumulative 5-yr survival rates were 45.3%.
Reverse sequence MIE is an efficient and safe procedure in treatment of esophageal patient cancers, which also greatly facilitates the procedure of esophagectomy.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.